Sandbox ap: Difference between revisions

Jump to navigation Jump to search
Line 154: Line 154:
| style="background:#F5F5F5;" + |Highest risk for VTE
| style="background:#F5F5F5;" + |Highest risk for VTE
|}
|}
==Pathophysiology of ILD==
{{Family tree/start}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q01= Insulin-like growth factor (IGF) signalling|Q02=Transforming growth factor (TGF)-β}}
{{Family tree| | | | | | | | | | | | Q01 | | | | | Q02 | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | P02 | | | | P03 | | P04 | | | | | | | | | | | | | | P02=IGF-binding protein 3 (IGFBP-3)|P03=IGF-binding protein 5 (IGFBP-5)|P04=Upregulation of Egr-1 (early growth response protein 1) }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | O02 | | | | | | | | | | | | | | | | | | | | | | | | | O02=Regulates transforming growth factor (TGF)-β }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | A02 | | | | | | | | | | | | | | | | | | | | | A02=Induction of syndecan-2 (SDC2)}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | B01=Activation,proliferation, and migration of fibroblast to the site of injury}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | | C01=Fibroblasts}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | D01 | | | | D02 | | | | | | | | | | | | | | | | D01=Altered PTEN (phosphatase and tensin homologue)/Akt axis|D02=Acquire contractile stress fibres}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | G01 | | | | G02 | | G03 | | | | | | | | | | | | G01= Inactivates Fox (forkhead box) O3a|G02=Protomyofibroblast,composed of cytoplasmic actins|G03=Pleural mesothelial cells (PMCs)}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | H01 | | | | H02 | | H03 | | | | | | | | | | | | H01= Downregulation of cav-1 and Fas expression|H02=De novo expression of α-SMA|H03=TGF-β1-dependent mesothelial–mesenchymal transition}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | I01 | | | | | | I02 | | | | | | | | | | | | | | | | I01=Fibroblast resistant to apoptosis|I02=Myofibroblasts}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | J02 | | J03 | | | | | | | | | | J02=Different ranges of contractions mediated by RhoA/Rho-associated kinase|J03=Changes in intracellular calcium concentrations}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | K02 | | | | | | | | | K04 | K02=Lock step mechanism of cyclic and contractile events}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | L02 | | | | | | L03 | | | | | | | | | K04 | L02=Excess ECM production|L03=Exerting traction force}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | M01 | | | | | | | | | | | | | | | | | M02 | M01=Tissue remodelling}}
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree| | | | | | | | | | | | | | | N01 | | | | | | | | | | | | | | | | | | N01=Lung Fibrosis}}
{{Family tree/end}}


==References==
==References==
<references />
<references />

Revision as of 17:56, 2 March 2018

==Classification Gastritis

Gastritis Etiology Gasstritis synonyms
Non-atrophic
  • Helicobacter pylori
  • Other factors

Superficial Diffuse antral gastritis (DAG) Chronic antral gastritis (CAG) Interstitial - follicular Hypersecretory Type B*

Atrophic Autoimmune
  • Autoimmunity

Type A* Diffuse corporal Pernicious anemia-associated

Multifocal atrophic Helicobacter pylori Type B*, type AB*
Dietary Environmental
Environmental factors Metaplastic
Special form Chemical Chemical irritation Reactive
  • Bile
  • Reflux
  • NSAIDs
  • NSAID
  • Other agents
  • Type C*
Radiation Radiation injury

Risk assessment table

Scoring criteria for risk assessment*
Scoring system Score Risk
IMPROVEDD Score[1] Predicted % VTE risk through 42 days
0 0.4%
1 0.6%
2 0.8%
3 1.2%
4 1.6%
5-10 2.2%
Predicted % VTE risk through 77 days
0 0.5%
1 0.7%
2 1.0%
3 1.4%
4 1.9%
5-10 2.75
IMPROVE score[2] Predicted % VTE risk through 3 months
0 0.5%
1 1.0%
2 1.7%
3 3.1%
4 4%
5-8 11%
Padua Score[3] < 4 Low risk for VTE
≥ 4 High risk for VTE
Caprini score[4] 0-1 Low risk of VTE
2 Moderate of VTE
3-4 High risk of VTE
≥ 5 Highest risk for VTE

Pathophysiology of ILD

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{{ Q01 }}}
 
 
 
 
{{{ Q02 }}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGF-binding protein 3 (IGFBP-3)
 
 
 
IGF-binding protein 5 (IGFBP-5)
 
Upregulation of Egr-1 (early growth response protein 1)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulates transforming growth factor (TGF)-β
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Induction of syndecan-2 (SDC2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activation,proliferation, and migration of fibroblast to the site of injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibroblasts
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altered PTEN (phosphatase and tensin homologue)/Akt axis
 
 
 
Acquire contractile stress fibres
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inactivates Fox (forkhead box) O3a
 
 
 
Protomyofibroblast,composed of cytoplasmic actins
 
Pleural mesothelial cells (PMCs)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Downregulation of cav-1 and Fas expression
 
 
 
De novo expression of α-SMA
 
TGF-β1-dependent mesothelial–mesenchymal transition
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibroblast resistant to apoptosis
 
 
 
 
 
Myofibroblasts
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Different ranges of contractions mediated by RhoA/Rho-associated kinase
 
Changes in intracellular calcium concentrations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lock step mechanism of cyclic and contractile events
 
 
 
 
 
 
 
 
{{{ K04 }}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excess ECM production
 
 
 
 
 
Exerting traction force
 
 
 
 
 
 
 
 
{{{ K04 }}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue remodelling
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{{ M02 }}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lung Fibrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

References

  1. . doi:10.1055/s-0037-160392910.1055/s-0037-1603929. Missing or empty |title= (help)
  2. Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH; et al. (2011). "Predictive and associative models to identify hospitalized medical patients at risk for VTE". Chest. 140 (3): 706–14. doi:10.1378/chest.10-1944. PMID 21436241.
  3. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M; et al. (2010). "A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score". J Thromb Haemost. 8 (11): 2450–7. doi:10.1111/j.1538-7836.2010.04044.x. PMID 20738765.
  4. Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F (1991). "Clinical assessment of venous thromboembolic risk in surgical patients". Semin Thromb Hemost. 17 Suppl 3: 304–12. PMID 1754886.